CELSION CORP(NASDAQ:CLSN) stock News

CLSN Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: The Motley Fool - Mentions: CMG MCD TJX RBLX ...

What's Eating at Restaurant Stocks?

3 years ago - By: Celsion Corporation

Celsion Corporation Announces Company Name Change to Imunon, Inc.

3 years ago - By: Benzinga - Mentions: ALNY INCY REGN EW ...

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

3 years ago - By: Celsion Corporation

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

3 years ago - By: Celsion Corporation

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

3 years ago - By: Benzinga

Recap: Celsion Q2 Earnings

3 years ago - By: Celsion Corporation

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

3 years ago - By: Celsion Corporation

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

3 years ago - By: Celsion Corporation

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

3 years ago - By: Celsion Corporation

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

3 years ago - By: Celsion Corporation

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

3 years ago - By: Celsion Corporation

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

3 years ago - By: Celsion Corporation

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

3 years ago - By: Celsion Corporation

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

3 years ago - By: Celsion Corporation

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

3 years ago - By: Celsion Corporation

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

3 years ago - By: Celsion Corporation

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

4 years ago - By: Celsion Corporation

CELSION CORP (CLSN) Stock News

CLSN Latest News, Press Relases and Analysis

What's Eating at Restaurant Stocks?

Celsion Corporation Announces Company Name Change to Imunon, Inc.

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

Recap: Celsion Q2 Earnings

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules